PeterAKaufmanMD

Oncology • Burlington, VT

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dartmouth Medical School

Join to view full profile

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaufman's full profile

Already have an account?

Office
Beaumont Ave
UVM Cancer Center
Burlington, VT 05403
Phone+1 603-653-6181

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1989
Duke University HospitalResidency, Internal Medicine, 1983 - 1986
New York University School of MedicineClass of 1983

Certifications & Licensure

VT State Medical License 1993 - 2026
NH State Medical License 1992 - 2020
NC State Medical License 1987 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

52 citations
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer...
Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz
Journal of Clinical Oncology. 2021-08-06
978 citations
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue
Journal of Clinical Oncology. 2017-06-03
544 citations
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH ...
George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue
JAMA Oncology. 2020-01-01

Lectures

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Breast Cancer: What We Know TodayJune 2nd, 2022
Laekna Therapeutics Announces Dosing of First Patients in the U.S. And China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast CancerMay 26th, 2022
UVM Students Contribute to Groundbreaking Cancer ResearchJune 9th, 2021